115450.KQ
HLB Therapeutics Co.,Ltd.
KOE · Healthcare · Biotechnology · KR
KRW 2,095.00
+0.96%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 64.6B | 69.7B | 54.9B | 53.7B | 42.4B |
| Cost of Revenue | 60.5B | 59.4B | 44.7B | 47.1B | 34.4B |
| Gross Profit | 4.1B | 9.4B | 10.2B | 6.7B | 8.0B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | 63.4M |
| SG&A Expense | 9.0B | 6.5B | 9.5B | 10.2B | 10.7B |
| General & Admin Expense | 1.3B | 1.6B | 1.5B | 1.3B | 1.2B |
| Selling & Marketing Expense | 2.0B | 4.8B | 8.0B | 8.9B | 9.6B |
| Other Expenses | 5.3B | 7.3B | 8.3B | 5.9B | (273.1M) |
| Total Operating Expenses | 13.0B | 13.7B | 17.8B | 16.1B | 15.5B |
| Cost and Expenses | 73.5B | 73.1B | 62.6B | 62.4B | 49.9B |
| Operating Income (EBIT) | (8.9B) | (3.6B) | (7.6B) | (8.7B) | (7.5B) |
| Non-Operating | |||||
| Interest Income | 6.1B | 6.3B | 984.5M | 1.3B | 1.2B |
| Interest Expense | 3.4B | 3.6B | 2.0B | 598.7M | 5.1B |
| Net Interest Income | 2.7B | 2.7B | (979.8M) | 678.2M | (3.9B) |
| Other Non-Op Income/Expense | (6.7B) | (7.5B) | (15.3B) | 5.9B | (6.0B) |
| Non-Operating Income (excl Interest) | 4.8B | 5.6B | 13.3B | (6.8B) | (1.1B) |
| EBT (Pre-Tax Income) | (15.6B) | (11.1B) | (22.9B) | (2.8B) | (13.5B) |
| Income Tax Expense | 1.2B | (1.4B) | (3.2B) | (730.00) | (2.1B) |
| Bottom Line | |||||
| Net Income | (16.2B) | (9.2B) | (22.8B) | (2.3B) | (11.4B) |
| Earnings from Cont. Ops | (16.8B) | (9.7B) | (19.8B) | (2.8B) | (11.6B) |
| Earnings from Discont. Ops | — | — | (534.1M) | (310.2M) | — |
| Bottom Line Net Income | (16.2B) | (9.2B) | (22.8B) | (2.3B) | (11.4B) |
| Per Share | |||||
| Basic EPS | (₩186) | (₩100) | (₩275) | (₩32) | (₩172) |
| Diluted EPS | (₩186) | (₩100) | (₩275) | (₩32) | (₩172) |
| Revenue Per Share | ₩733 | ₩831 | ₩663 | ₩750 | ₩642 |
| Shares | |||||
| Basic Shares Outstanding | 88.1M | 83.9M | 82.8M | 71.7M | 66.0M |
| Diluted Shares Outstanding | 88.1M | 83.9M | 82.8M | 71.7M | 66.0M |
| Profitability Metrics | |||||
| EBITDA | (7.1B) | 1.0B | (9.7B) | 6.6B | (4.8B) |
| D&A | 2.3B | 4.6B | 8.1B | 8.5B | 1.7B |
| EBIT | (8.8B) | (3.6B) | (17.8B) | (1.9B) | (6.4B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026